Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;33(10):e13860.
doi: 10.1111/pai.13860.

Chilblains outbreak during COVID-19 pandemic: A Type-I interferonopathy?

Affiliations

Chilblains outbreak during COVID-19 pandemic: A Type-I interferonopathy?

Anna Mensa-Vilaró et al. Pediatr Allergy Immunol. 2022 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest relevant to this article to disclose.

Figures

FIGURE 1
FIGURE 1
Skin lesions observed in patients. (A) Bilateral purple to red, chilblain‐like lesions on toes. (B) Central darkening could be seen in some lesions. (C) Violaceous discoloration could also occur on the hands. (D) Lesions could also be present on heels and could become necrotic or bullous.
FIGURE 2
FIGURE 2
Type‐I IFN signature of COVID‐toes patients (n: 24) compared with healthy controls (HC; n: 26) and monogenic type‐I interferonopathies (disease control, DC; n: 6). Panel A. 28‐IRG score of COVID‐toes patients, HC and DC. Patients with COVID‐toes show no statistically significant differences in IFN Z‐score compared with HC and differ from DC patients. Panel B. 28‐IRG score of COVID‐toes patients clustered according to the duration of chilblains at evaluation, HC and DC. Patients with COVID‐toes evaluated before 7 days of onset of the skin lesions show statistical increase in 28‐IRG score compared with patients who started later than 7 days. Horizontal dotted line represents the cutoff of 28‐IRG score (≥1.7) from which we considered a positive IFN score. 28‐IRG was calculated following previous publication J Interferon Cytokine Res 2018; 38:171–185. Data are presented as scattered dot plots; the horizontal bar represents the mean, and the whiskers represent the standard error of mean. Only statistically significant differences are depicted. ** denotes p < .01. ns, not significant.

References

    1. Freeman EE, McMahon DE, Lipoff JB, et al. Pernio‐like skin lesions associated with COVID‐19: a case series of 318 patients from 8 countries. J Am Acad Dermatol. 2020;83:486‐492. - PMC - PubMed
    1. Andina D, Noguera‐Morel L, Bascuas‐Arribas M, et al. Chilblains in children in the setting of COVID‐19 pandemic. Pediatr Dermatol. 2020;37:406‐411. - PMC - PubMed
    1. Docampo‐Simon A, Sanchez‐Pujol MJ, Gimeno‐Gascon A, et al. No SARS‐CoV‐2 antibody response in 25 patients with pseudo‐chilblains. Dermatol Ther. 2020;33:e14332. - PMC - PubMed
    1. Colmenero I, Santonja C, Alonso‐Riaño M, et al. SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br J Dermatol. 2020;183:729‐737. - PMC - PubMed
    1. Ko CJ, Harigopal M, Gehlhausen JR, Bosenberg M, McNiff JM, Damsky W. Discordant anti‐SARS‐CoV‐2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein. J Cutan Pathol. 2021;48:47‐52. - PubMed

Publication types